{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:03:39Z","timestamp":1789682619008,"version":"4.0.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","redjournal.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.ijrobp.2024.10.039","type":"journal-article","created":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T11:16:31Z","timestamp":1731582991000},"page":"930-941","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Phase 1 Study of Adjuvant Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor\u2013Transduced Pancreatic Tumor Cell Vaccine, Low-Dose Cyclophosphamide, and Stereotactic Body Radiation Therapy Followed by FOLFIRINOX in High-Risk Resected Pancreatic Ductal Adenocarcinoma"],"prefix":"10.1016","volume":"121","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8226-8566","authenticated-orcid":false,"given":"Colin S.","family":"Hill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rose","family":"Parkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M.","family":"Jaffee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Sugar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Onners","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher L.","family":"Wolfgang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Cameron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy M.","family":"Pawlik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Rosati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dung T.","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Hacker-Prietz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric R.","family":"Lutz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Schulick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amol K.","family":"Narang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Laheru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph M.","family":"Herman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2024.10.039_bib0001","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.4708","article-title":"Estimated projection of US cancer incidence and death to 2040","volume":"4","author":"Rahib","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ijrobp.2024.10.039_bib0002","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1001\/jama.2013.279201","article-title":"Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: The CONKO-001 randomized trial","volume":"310","author":"Oettle","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.ijrobp.2024.10.039_bib0003","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa032295","article-title":"A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer","volume":"350","author":"Neoptolemos","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2024.10.039_bib0004","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1200\/JCO.22.01134","article-title":"Adjuvant nab-paclitaxel + gemcitabine in resected pancreatic ductal adenocarcinoma: Results from a randomized, open-label, phase III trial","volume":"41","author":"Tempero","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2024.10.039_bib0005","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/jamaoncol.2022.3829","article-title":"Five-year outcomes of FOLFIRINOX vs gemcitabine as adjuvant therapy for pancreatic cancer: A randomized clinical trial","volume":"8","author":"Conroy","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2024.10.039_bib0006","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(16)32409-6","article-title":"Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): A multicentre, open-label, randomised, phase 3 trial","volume":"389","author":"Neoptolemos","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2024.10.039_bib0007","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1200\/JCO.19.02274","article-title":"Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: Results of the DUTCH randomized phase III PREOPANC trial","volume":"38","author":"Versteijne","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2024.10.039_bib0008","doi-asserted-by":"crossref","first-page":"4141","DOI":"10.1002\/cncr.29652","article-title":"Addition of radiotherapy to adjuvant chemotherapy is associated with improved overall survival in resected pancreatic adenocarcinoma: An analysis of the national cancer data base","volume":"121","author":"Rutter","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2024.10.039_bib0009","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1002\/cam4.1479","article-title":"Adjuvant radiotherapy and chemotherapy improve survival in patients with pancreatic adenocarcinoma receiving surgery: Adjuvant chemotherapy alone is insufficient in the era of intensity modulation radiation therapy","volume":"7","author":"Hsieh","year":"2018","journal-title":"Cancer Med"},{"key":"10.1016\/j.ijrobp.2024.10.039_bib0010","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1200\/JCO.2008.17.7188","article-title":"DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer","volume":"27","author":"Iacobuzio-Donahue","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2024.10.039_bib0011","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1002\/cam4.4527","article-title":"High local failure rates despite high margin-negative resection rates in a cohort of borderline resectable and locally advanced pancreatic cancer patients treated with stereotactic body radiation therapy following multi-agent chemotherapy","volume":"11","author":"Hill","year":"2022","journal-title":"Cancer Med"},{"key":"10.1016\/j.ijrobp.2024.10.039_bib0012","doi-asserted-by":"crossref","first-page":"711","DOI":"10.6004\/jnccn.2018.7013","article-title":"Clinical impact of local progression in pancreatic cancer","volume":"16","author":"Cardillo","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ijrobp.2024.10.039_bib0013","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1001\/archsurg.1985.01390320023003","article-title":"Pancreatic cancer: Adjuvant combined radiation and chemotherapy following curative resection","volume":"120","author":"Kalser","year":"1985","journal-title":"Arch Surg"},{"key":"10.1016\/j.ijrobp.2024.10.039_bib0014","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1097\/00000658-199912000-00006","article-title":"Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: Phase III trial of the EORTC gastrointestinal tract cancer cooperative group","volume":"230","author":"Klinkenbijl","year":"1999","journal-title":"Ann Surg"},{"key":"10.1016\/j.ijrobp.2024.10.039_bib0015","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1097\/SLA.0b013e318156eef3","article-title":"Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: Long-term results of EORTC trial 40891","volume":"246","author":"Smeenk","year":"2007","journal-title":"Ann Surg"},{"key":"10.1016\/j.ijrobp.2024.10.039_bib0016","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1245\/s10434-011-1630-6","article-title":"Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup\/RTOG 9704 phase III trial","volume":"18","author":"Regine","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ijrobp.2024.10.039_bib0017","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.ijrobp.2010.07.1993","article-title":"The influence of total nodes examined, number of positive nodes, and lymph node ratio on survival after surgical resection and adjuvant chemoradiation for pancreatic cancer: A secondary analysis of RTOG 9704","volume":"81","author":"Showalter","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.10.039_bib0018","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/cncr.29161","article-title":"Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma","volume":"121","author":"Herman","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2024.10.039_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2019.10.013","article-title":"Efficacy and feasibility of stereotactic radiotherapy after FOLFIRINOX in patients with locally advanced pancreatic cancer (LAPC-1 trial)","volume":"17","author":"Suker","year":"2019","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.ijrobp.2024.10.039_bib0020","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.radonc.2020.11.006","article-title":"A phase II study of stereotactic radiotherapy after FOLFIRINOX for locally advanced pancreatic cancer (LAPC-1 trial): Long-term outcome","volume":"155","author":"Teriaca","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2024.10.039_bib0021","doi-asserted-by":"crossref","first-page":"979","DOI":"10.3109\/0284186X.2015.1004367","article-title":"Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma","volume":"54","author":"Mellon","year":"2015","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ijrobp.2024.10.039_bib0022","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1245\/s10434-021-11202-8","volume":"29","author":"Hill","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ijrobp.2024.10.039_bib0023","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.adro.2018.11.007","article-title":"Initial results of a prospective study of adjuvant pancreatic stereotactic body radiation therapy for close or positive margins","volume":"4","author":"Bernard","year":"2019","journal-title":"Adv Radiat Oncol"},{"issue":"2","key":"10.1016\/j.ijrobp.2024.10.039_bib0024","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/SLA.0b013e3181fd271c","article-title":"A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A phase II trial of safety, efficacy, and immune activation","volume":"253","author":"Lutz","year":"2011","journal-title":"Ann Surg"},{"issue":"3","key":"10.1016\/j.ijrobp.2024.10.039_bib0025","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ijrobp.2015.11.026","article-title":"Lymphocyte-sparing effect of stereotactic body radiation therapy in patients with unresectable pancreatic cancer","volume":"94","author":"Wild","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.ijrobp.2024.10.039_bib0026","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.ijrobp.2013.09.005","article-title":"Mapping patterns of local recurrence after pancreaticoduodenectomy for pancreatic adenocarcinoma: A new approach to adjuvant radiation field design","volume":"87","author":"Dholakia","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.10.039_bib0027","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1200\/JCO.2007.15.8469","article-title":"Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: Results of a large, prospectively collected database at the Johns Hopkins Hospital","volume":"26","author":"Herman","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2024.10.039_bib0032","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1097\/MPA.0b013e31829e2006","article-title":"Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma","volume":"42","author":"Mahaseth","year":"2013","journal-title":"Pancreas"},{"key":"10.1016\/j.ijrobp.2024.10.039_bib0033","series-title":"The Annual Meeting of the October","article-title":"Results of adjuvant chemotherapy +\/- chemoradiation for patients with resected periampullary pancreatic adenocarcinoma: NRG Oncology\/RTOG 0848, Paper presented at","author":"Abrams","year":"2022"},{"key":"10.1016\/j.ijrobp.2024.10.039_bib0034","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1001\/jamaoncol.2022.2319","article-title":"Efficacy of preoperative mFOLFIRINOX vs mFOLFIRINOX plus hypofractionated radiotherapy for borderline resectable adenocarcinoma of the pancreas: The A021501 phase 2 randomized clinical trial","volume":"8","author":"Katz","year":"2022","journal-title":"JAMA Oncol"},{"issue":"16_suppl","key":"10.1016\/j.ijrobp.2024.10.039_bib0035","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.1200\/JCO.2022.40.16_suppl.4008","article-title":"Randomized phase III trial of induction chemotherapy followed by chemoradiotherapy or chemotherapy alone for nonresectable locally advanced pancreatic cancer: First results of the CONKO-007 trial","volume":"40","author":"Fietkau","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2024.10.039_bib0036","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2008.09.037","article-title":"Immunosurveillance of pancreatic adenocarcinoma: Insights from genetically engineered mouse models of cancer","volume":"279","author":"Clark","year":"2009","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ijrobp.2024.10.039_bib0037","doi-asserted-by":"crossref","first-page":"5423","DOI":"10.1158\/1078-0432.CCR-06-0369","article-title":"Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions","volume":"12","author":"Hiraoka","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2024.10.039_bib0038","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/0923-2494(91)90042-H","article-title":"T-cell immunotherapy of cancer","volume":"142","author":"Melief","year":"1991","journal-title":"Res Immunol"},{"key":"10.1016\/j.ijrobp.2024.10.039_bib0039","first-page":"925s","article-title":"Systemic and local immunosuppression in pancreatic cancer patients","volume":"7","author":"von Bernstorff","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2024.10.039_bib0040","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/267539","article-title":"Current immunotherapeutic approaches in pancreatic cancer","volume":"2011","author":"Koido","year":"2011","journal-title":"Clin Dev Immunol"},{"issue":"7","key":"10.1016\/j.ijrobp.2024.10.039_bib0028","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/CJI.0b013e31829fb7a2","article-title":"Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer","volume":"36","author":"Le","year":"2013","journal-title":"J Immunother"},{"issue":"1","key":"10.1016\/j.ijrobp.2024.10.039_bib0031","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CJI.0000000000000062","article-title":"PD-1\/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors","volume":"38","author":"Soares","year":"2015","journal-title":"J Immunother"},{"key":"10.1016\/j.ijrobp.2024.10.039_bib0041","doi-asserted-by":"crossref","first-page":"e498","DOI":"10.1016\/S1470-2045(15)00007-8","article-title":"Radiation and checkpoint blockade immunotherapy: Radiosensitisation and potential mechanisms of synergy","volume":"16","author":"Sharabi","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2024.10.039_bib0042","doi-asserted-by":"crossref","first-page":"43039","DOI":"10.18632\/oncotarget.9915","article-title":"Combination of radiotherapy and vaccination overcomes checkpoint blockade resistance","volume":"7","author":"Zheng","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ijrobp.2024.10.039_bib0043","doi-asserted-by":"crossref","first-page":"167","DOI":"10.15252\/emmm.201606674","article-title":"PD-L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy","volume":"9","author":"Azad","year":"2017","journal-title":"EMBO Mol Med"},{"issue":"4_suppl","key":"10.1016\/j.ijrobp.2024.10.039_bib0045","doi-asserted-by":"crossref","first-page":"TPS758","DOI":"10.1200\/JCO.2023.41.4_suppl.TPS758","article-title":"A phase I study of a mutant KRAS-targeted long peptide vaccine in patients at high risk of developing pancreatic cancer","volume":"41","author":"Haldar","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2024.10.039_bib0046","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.ijrobp.2024.10.039_bib0047","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.prro.2022.01.005","article-title":"Location, Location, Location: What Should be Targeted Beyond Gross Disease for Localized Pancreatic Ductal Adenocarcinoma? Proposal of a Standardized Clinical Tumor Volume for Pancreatic Ductal Adenocarcinoma of the Head: The \"Triangle Volume","volume":"12","author":"Hill","year":"2022","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2024.10.039_bib0048","doi-asserted-by":"crossref","first-page":"368","DOI":"10.21037\/jgo-21-513","article-title":"High neutrophil-to-lymphocyte ratio following stereotactic body radiation therapy is associated with poor clinical outcomes in patients with borderline resectable and locally advanced pancreatic cancer","volume":"13","author":"Reddy","year":"2022","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.ijrobp.2024.10.039_bib0049","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jamaoncol.2020.7328","article-title":"Efficacy of perioperative chemotherapy for resectable pancreatic adenocarcinoma: A phase 2 randomized clinical trial","volume":"7","author":"Sohal","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2024.10.039_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.110064","article-title":"Stereotactic MR-guided on-table adaptive radiation therapy (SMART) for borderline resectable and locally advanced pancreatic cancer: A multi-center, open-label phase 2 study","volume":"191","author":"Chuong","year":"2024","journal-title":"Radiother Oncol"},{"issue":"7","key":"10.1016\/j.ijrobp.2024.10.039_bib0051","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1158\/2326-6066.CIR-14-0027","article-title":"Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation","volume":"2","author":"Lutz","year":"2014","journal-title":"Cancer Immunol Res"},{"issue":"12","key":"10.1016\/j.ijrobp.2024.10.039_bib0052","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1200\/JCO.2014.57.4244","article-title":"Safety and survival with GVAX pancreas prime and listeria monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer","volume":"33","author":"Le","year":"2015","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ijrobp.2024.10.039_bib0053","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1158\/1078-0432.CCR-07-0371","article-title":"Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation","volume":"14","author":"Laheru","year":"2008","journal-title":"Clin Cancer Res"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301624035612?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301624035612?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T10:47:29Z","timestamp":1740134849000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301624035612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0360301624035612"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2024.10.039","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase 1 Study of Adjuvant Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor\u2013Transduced Pancreatic Tumor Cell Vaccine, Low-Dose Cyclophosphamide, and Stereotactic Body Radiation Therapy Followed by FOLFIRINOX in High-Risk Resected Pancreatic Ductal Adenocarcinoma","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2024.10.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}